XmAb®5574, An Fc Engineered Humanized Anti-CD19 Monoclonal Antibody, Has Potent in Vitro and in Vivo Activities, and Has the Potential for Treating B Cell MalignanciesChris E. Lawrence, David F. Carmichael, Seung Y. Chu et al.|Blood|2008Cited by 1
Inhibition of B Cell Receptor-Mediated B Cell Activation and IgE secretion by Coengagement of Surface IgE and FcγRIIb with Fc-Engineered AntibodiesDavid E. Szymkowski, John R. Desjarlais, Holly Horton et al.|Journal of Allergy and Clinical Immunology|2010Cited by 0